REGN Stock Summary and Trading Ideas (Regeneron Pharmaceuticals | NASDAQ:REGN)

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.

As of December 20, 2024, REGN stock price declined to $701.85 with 1,482,414 million shares trading.

REGN has a beta of 0.88, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.17 to the broad based SPY ETF.

REGN has a market cap of $77.13 billion. This is considered a Large Cap stock.

Last quarter Regeneron Pharmaceuticals reported $4 billion in Revenue and $12.46 earnings per share. This beat revenue expectation by $51 million and exceeded earnings estimates by $.77.

In the last 3 years, REGN traded as high as $1,211.20 and as low as $538.01.

The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, VOO, QQQ, SPY, IVV.

REGN has underperformed the market in the last year with a price return of -16.6% while the SPY ETF gained +27.8%. REGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.7% and -9.8%, respectively, while the SPY returned +4.4% and -2.4%, respectively.

REGN support price is $695.61 and resistance is $720.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.